SENS Stock Risk & Deep Value Analysis
Senseonics Holdings Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About SENS Stock
We analyzed Senseonics Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SENS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
SENS Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Upcoming Risk Events
- 📅
Delay or rejection of 365-day Eversense FDA approval
- 📅
Weaker-than-expected Q4 2025 earnings or guidance
- 📅
Further significant equity dilution to fund operations
- 📅
Intensified competition from Dexcom or Abbott product innovations
Unlock SENS Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Senseonics Holdings Inc (SENS) Do?
Market Cap
$16.65M
Sector
Healthcare
Industry
Medical Devices
Employees
117
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Visit Senseonics Holdings Inc WebsiteInvestment Thesis
Senseonics is a highly speculative investment centered on its differentiated Eversense long-term implantable CGM technology. The potential FDA approval and commercial success of its 365-day sensor, distributed through Ascensia, represents the primary catalyst for significant upside. If successful, its unique convenience could carve out a substantial niche in the growing diabetes market, justifying a much higher valuation despite current financial struggles and intense competition.
Is SENS Stock Undervalued?
Unlock the full AI analysis for SENS
Get the complete DVR score, risk analysis, and more
SENS Price Targets & Strategy
12-Month Target
$9.50
Bull Case
$20.00
Bear Case
$2.50
Entry Strategy
Dollar-cost average below $7.00, only for highly aggressive portfolios.
Exit Strategy
Take 50% profit at $15.00, review at $20.00. Stop loss at $4.00.
Portfolio Allocation
1-3% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does SENS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
The moat's durability is largely dependent on the successful regulatory approval and widespread adoption of its 365-day sensor. If this pivotal product fails to gain traction or approval, the current moat against well-established and well-funded competitors like Dexcom and Abbott would be severely eroded. The unique implantable nature provides a niche, but not a dominant, advantage without market leadership in that niche.
Moat Erosion Risks
- •Competitors developing their own long-duration or implantable solutions
- •Failure to secure broad insurance coverage for new sensor durations
- •Slow adoption rates due to perceived invasiveness or procedural burden
SENS Competitive Moat Analysis
Sign up to see competitive advantages
SENS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral
Institutional Sentiment
Neutral
Insider Activity (Form 4)
No significant recent insider buying or selling detected that would indicate strong conviction change.
Options Flow
Implied volatility is typically high, indicating significant uncertainty. Call activity suggests speculative interest in upside potential, but put volume indicates hedging or bearish bets.
Earnings Intelligence
Next Earnings
Estimated Early-May 2026 (for Q1 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Stock price often experiences significant volatility post-earnings, heavily influenced by forward guidance and updates on regulatory progress or commercialization efforts.
Key Metrics to Watch
Competitive Position
Top Competitor
DXCM
Market Share Trend
Losing/Stable (in the broader CGM market); potential for significant gains in the niche long-term implantable segment if 365-day is successful.
Valuation vs Peers
SENS trades at a significant discount on traditional valuation metrics (e.g., EV/Sales) compared to profitable peers like Dexcom and Abbott, primarily due to its lack of profitability, lower revenue base, and higher risk profile. Its valuation is largely speculative, based on future potential rather than current fundamentals.
Competitive Advantages
- •Unique long-term implantable CGM technology (Eversense E3)
- •Potential for 365-day wear duration (if approved), offering unparalleled convenience
- •Strategic global commercialization partnership with Ascensia Diabetes Care
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive SENS Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Expected early-March 2026)
- •Updates on 365-day Eversense FDA submission progress
- •Ascensia commercialization updates and sales figures
Medium-Term (6-18 months)
- •Potential FDA approval for 365-day Eversense system (6-12 months)
- •Initial launch and commercial ramp-up of 365-day sensor
- •Expansion of insurance coverage for Eversense systems
Long-Term (18+ months)
- •Widespread adoption of 365-day Eversense, significant market share gains in long-term CGM segment
- •Achievement of consistent profitability and positive free cash flow
- •Next-generation sensor development or geographic expansion
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SENS?
- ✓
Announcement of FDA approval for the 365-day Eversense sensor
- ✓
Significant acceleration in revenue growth and positive gross margin trends
- ✓
Demonstrable reduction in cash burn and progress towards profitability
Bull Case Analysis
See what could go right with Premium
Competing with SENS
See how Senseonics Holdings Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Senseonics Holdings Inc SENS | $16.6M | 1.0 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Dexcom Inc DXCM | $26.2B | 6.6 | 32.4 | $4.7B | 17.9% | 13.1% | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Senseonics Holdings Inc (SENS)?
As of March 19, 2026, Senseonics Holdings Inc has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Senseonics Holdings Inc?
Senseonics Holdings Inc's market capitalization is approximately $16.6M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Senseonics Holdings Inc use?
SENS is the ticker symbol for Senseonics Holdings Inc. The company trades on the ASE.
What is the risk level for SENS stock?
Our analysis rates Senseonics Holdings Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the SENS DVR analysis updated?
Our AI-powered analysis of Senseonics Holdings Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 19, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SENS (Senseonics Holdings Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.